Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1985 Oct;52(4):613–617. doi: 10.1038/bjc.1985.234

The effect of etoposide on human CFU-GM.

R Bailey-Wood, C M Dallimore, T J Littlewood, D P Bentley
PMCID: PMC1977245  PMID: 4063137

Abstract

Etoposide is being used increasingly in the treatment of a variety of malignant conditions and in conjunction with autologous bone marrow transplantation. We have examined the effect of the drug on human CFU-GM as an indication of the response of these bone marrow progenitor cells to measured plasma concentrations. When etoposide is present in the routine assay for 7 days, 50% growth of colony-forming CFU-GM occurs at a concentration of 0.0098 micrograms ml-1. When bovine serum albumin or human serum albumin is present this value is increased to 0.042 and 0.375 micrograms ml-1. Protein binding therefore plays an important part in modifying in vitro response and possibly in vivo response of these progenitor cells to etoposide.

Full text

PDF
613

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allen L. M., Creaven P. J. Comparison of the human pharmacokinetics of VM-26 and VP-16, two antineoplastic epipodophyllotixin glucopyranoside derivatives. Eur J Cancer. 1975 Oct;11(10):697–707. doi: 10.1016/0014-2964(75)90043-2. [DOI] [PubMed] [Google Scholar]
  2. Bailey-Wood R., Dallimore C. M., Whittaker J. A. Effect of adriamycin on CFUGM at plasma concentrations found following therapeutic infusions. Br J Cancer. 1984 Sep;50(3):351–355. doi: 10.1038/bjc.1984.182. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Cavalli F., Sonntag R. W., Jungi F., Senn H. J., Brunner K. W. VP-16-213 monotherapy for remission induction of small cell lung cancer: a randomized trial using three dosage schedules. Cancer Treat Rep. 1978 Mar;62(3):473–475. [PubMed] [Google Scholar]
  4. Evans W. E., Sinkule J. A., Crom W. R., Dow L., Look A. T., Rivera G. Pharmacokinetics of Teniposide (VM26) and etoposide (VP16-213) in children with cancer. Cancer Chemother Pharmacol. 1982;7(2-3):147–150. doi: 10.1007/BF00254537. [DOI] [PubMed] [Google Scholar]
  5. Grieder A., Maurer R., Stähelin H. Effect of an epipodophyllotoxin derivative (VP 16-213) on macromolecular synthesis and mitosis in mastocytoma cells in vitro. Cancer Res. 1974 Aug;34(8):1788–1793. [PubMed] [Google Scholar]
  6. Kalwinsky D. K., Look A. T., Ducore J., Fridland A. Effects of the epipodophyllotoxin VP-16-213 on cell cycle traverse, DNA synthesis, and DNA strand size in cultures of human leukemic lymphoblasts. Cancer Res. 1983 Apr;43(4):1592–1597. [PubMed] [Google Scholar]
  7. Loike J. D., Horwitz S. B. Effect of VP-16-213 on the intracellular degradation of DNA in HeLa cells. Biochemistry. 1976 Dec 14;15(25):5443–5448. doi: 10.1021/bi00670a004. [DOI] [PubMed] [Google Scholar]
  8. Misra N. C., Roberts D. W. Inhibition by 4'-demethyl-epipodophyllotoxin 9-(4,6-O-2-thenylidene-beta-D-glucopyranoside) of human lymphoblast cultures in G2 phase of the cell cycle. Cancer Res. 1975 Jan;35(1):99–105. [PubMed] [Google Scholar]
  9. Newlands E. S., Bagshawe K. D. Anti-tumour activity of the epipodophyllin derivative VP16-213 (etoposide: NSC-141540) in gestational choriocarcinoma. Eur J Cancer. 1980 Mar;16(3):401–405. doi: 10.1016/0014-2964(80)90359-x. [DOI] [PubMed] [Google Scholar]
  10. Radice P. A., Bunn P. A., Jr, Ihde D. C. Therapeutic trials with VP-16-213 and VM-26: active agents in small cell lung cancer, non-Hodgkin's lymphomas, and other malignancies. Cancer Treat Rep. 1979 Aug;63(8):1231–1239. [PubMed] [Google Scholar]
  11. Rivera G., Avery T., Roberts D. W. Response of L1210 to combinations of cytosine arabinoside and VM-26 or VP16-213. Eur J Cancer. 1975 Sep;11(9):639–647. doi: 10.1016/0014-2964(75)90099-7. [DOI] [PubMed] [Google Scholar]
  12. Stähelin H. 4'-Demethyl-epipodophyllotoxin thenylidene glucoside (VM 26), a podophyllum compound with a new mechanism of action. Eur J Cancer. 1970 Aug;6(4):303–311. doi: 10.1016/0014-2964(70)90095-2. [DOI] [PubMed] [Google Scholar]
  13. Wolff S. N., Fer M. F., McKay C. M., Hande K. R., Hainsworth J. D., Greco F. A. High-dose VP-16-213 and autologous bone marrow transplantation for refractory malignancies: a phase I study. J Clin Oncol. 1983 Nov;1(11):701–705. doi: 10.1200/JCO.1983.1.11.701. [DOI] [PubMed] [Google Scholar]
  14. Wozniak A. J., Ross W. E. DNA damage as a basis for 4'-demethylepipodophyllotoxin-9-(4,6-O-ethylidene-beta-D-glucopyranoside) (etoposide) cytotoxicity. Cancer Res. 1983 Jan;43(1):120–124. [PubMed] [Google Scholar]
  15. Yalowich J. C., Goldman I. D. Analysis of the inhibitory effects of VP-16-213 (etoposide) and podophyllotoxin on thymidine transport and metabolism in Ehrlich ascites tumor cells in vitro. Cancer Res. 1984 Mar;44(3):984–989. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES